 |
| Research article summary (published 20 Sep 2001): |
A comparative study of the effects of carbamazepine and the NMDA receptor antagonist remacemide on road tracking and car-following performance in actual traffic.
Full Abstract
RATIONALE:
Antiepileptic drugs are known to produce side effects which may impair driving performance. Performance effects, however, may differ substantially between individual antiepileptic drugs.
OBJECTIVE:
To compare the effects of carbamazepine, remacemide, and placebo on actual driving performance during a 12-day incremental dosing regimen.
METHODS:
Twenty-two healthy volunteers participated in a three-way, double-blind, cross-over driving study. Treatment effects were assessed in two actual driving tests carried out on days 8, 10, and 12 of each treatment period. The Road Tracking Test involved driving an instrumented vehicle at a constant speed and steady lateral position between the delineated lane boundaries. Standard deviation of lateral position (SDLP) was measured to indicate precision of road tracking control. The Car-Following Test involved driving the same vehicle behind a leading car and maintaining that distance while the latter executed a series of deceleration/acceleration maneuvers. Time to speed adaptation (TSA) and brake reaction time were the primary measures.
RESULTS:
Remacemide did not affect the subjects' driving performance. Carbamazepine increased SDLP throughout treatment and lengthened TSA on day 8. Changes in SDLP relative to placebo were comparable to those previously seen in drivers conducting the same test with blood alcohol concentrations of 0.05 g/dl.
CONCLUSION:
Remacemide, at the given dose regimen, does not affect driving performance. Carbamazepine, at the given dose regimen, can produce mild but sufficient impairment to put epileptic patients at risk when driving, at least during initiation therapy.
Learn Faster Today Improve your study skills
Author information
Author/s: Ramaekers, G (G); Lamers, J (J); Verhey, F (F); Muntjewerff, D (D); Mobbs, E (E); Sanders, N (N); Lewis, M (M); Lockton, A (A);
Affiliation: Experimental Psychopharmacology Unit, Brain and Behavior Institute, Faculty of Psychology, Maastricht University, PO Box 616, 6200 MD, Maastricht, The Netherlands. j.ramaekers(-atsign-)psychology.unimaas.nl
Journal and publication information
Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal: Psychopharmacology (Psychopharmacology (Berl)), published in Germany. (Language: eng)
Reference: 2002-Jan; vol 159 (issue 2) : pp 203-10
Dates: Created 2002/02/25; Completed 2002/04/02; Revised 2006/11/15;
PMID: 11862350, status: MEDLINE (last retrieval date: 11/6/2008)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article (including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
|
|
Related articles
This article has not been indexed for related articles as yet, however you can still use the live related article search links below.
See a large map of 100+ related articles.